BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
Go back to BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM| (NASDAQ: BBIO) | Delayed: 66.61 -0.7 (1.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $67.31 | 52 Week High | $ | |||
| Open | $67.39 | 52 Week Low | $ | |||
| Day High | $67.56 | P/E | N/A | |||
| Day Low | $66.10 | EPS | $ | |||
| Volume | 4,103,478 | |||||
